POS1065 IMPACT OF HYPERURICEMIA ON CLINICAL PHENOTYPE, COMORBIDITIES, AND RESPONSE TO SECUKINUMAB IN PSORIATIC ARTHRITIS: POST HOC ANALYSIS OF FUTURE AND MAXIMISE STUDIES

Background Hyperuricemia (HU) is a metabolic abnormality associated with psoriasis (PsO) and psoriatic arthritis (PsA) 1 . The prevalence of HU 2–13% in general population, 19–20% PsO patients (pts), 27–32% PsA pts 1,2 Pts PsO/PsA are at significantly increased risk development gout pathogenic role chronic the maintenance based on epidemiological, clinical, fundamental arguments hence does not appear fortuitous. These processes can influence each other 3 Moreover, has been shown to be more peripheral, destructive, challenging treat 4 Objectives To evaluate impact terms clinical presentation, severity, comorbidities, response secukinumab (SEC) over 1-year. Methods This post hoc analysis included pooled data from enrolled FUTURE 2–5 MAXIMISE phase trials. were stratified into 2 groups baseline (BL) serum uric acid (SUA) level (HU: ≥360 µmol/L; without HU: <360 µmol/L no history and/or lowering therapies [ULT]). Demographic disease characteristics, therapeutic history, comorbidities data, collected BL. Evaluations ACR20/50/70 responses, Psoriasis Area Severity Index (PASI) 90 response, resolution enthesitis dactylitis, Health Assessment Questionnaire Disability (HAQ-DI), mean change SUA level, up Week 52. All analyses performed descriptive presented as observed. Results Overall, 2504 analysis, which 822 (32.8%) had (62 [2.5%] gout; 49 [2.0%] treated ULT). At BL, mostly male (76.0% vs 34.2%) higher body mass index (30.9 28.3 kg/m ) such hypertension (43.8% 31.3%), compared HU. A proportion dactylitis (34.5% 25.9%), (48.3% 36.3%) greater PASI score (13.6 10.2), (Table 1). achieving ACR50, enthesitis/dactylitis, HAQ-DI comparable 52 irrespective BL status. PASI90 rate was SEC 150 mg (with load) similar 300 group status (Figure Table 1. Demographics characteristics Parameters, ± SD unless specified With hyperuricemia (N=822 Without (N=1682 Age (Years) 48.5 12.41 48.3 12.19 Gender (Male), n (%) 625 (76.0) 576 (34.2) Weight (kg) 92.71 18.62 79.59 17.55 BMI (kg/m 30.90 5.86 28.33 5.91 History hypertension, 360 (43.8) 526 (31.3) diabetes mellitus, 85 (10.3) 144 (8.6) TJC 20.6 15.52 21.3 16.25 SJC 10.9 9.31 10.8 9.13 Enthesitis, 412 (50.1) 852 (50.7) Dactylitis, 284 (34.5) 436 (25.9) Evidence current psoriasis; 397 (48.3) 611 (36.3) Mean score* 13.61 11.03 10.16 TNFi naїve, 477 (58.0) 938 (55.8) MTX use randomization, 321 (39.1) 685 (40.7) Serum (µmol/L) 420.7 57.11 274.9 51.98 CRP (mg/L) 11.6 18.66 10.7 23.36 *not MAXMISE BMI, index; CRP, C-reactive protein; MTX, methotrexate; SJC, swollen joint count; TJC, tender TNFi, tumor necrosis factor inhibitor Conclusion In this studies, reported PsO, Efficacy across all musculoskeletal manifestations mg; while slightly better mg, status, References [1]Tripolino C, et al. Front Med 2021;8:737573 [2]AlJohani R, al J Rheumatol. 2018;45(2):213–7 [3]Felten Clin Rheumatol 2020;39:1405–13 [4]Widawski L, 2022. https://doi.org/10.1007/s10067-022-06061-x Disclosure Interests Renaud FELTEN Consultant of: Novartis (Advisory board), Laura Widawski: None declared, Lionel Spielmann: Corine Gaillez Shareholder Novartis, Employee Weibin Bao Jacques-Eric Gottenberg Pierre-Marie Duret: Laurent Messer: declared